Disease · MONDO_0005575
Comparisons in its trials324
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 324
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Panitumumab vs Concomitant Administration of Panitumumab and Chemotherapy: serious adverse events | 614 of 1,254 | 747 of 1,831 | 3,085 | NCT02089737 | Trial comparisons |
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: deaths from any cause | 507 of 624 | 499 of 629 | 1,253 | NCT02753127 | Trial comparisons |
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: serious adverse events | 234 of 622 | 201 of 610 | 1,232 | NCT02753127 | Trial comparisons |
| Aflibercept/FOLFIRI vs Placebo/FOLFIRI: serious adverse events | 294 of 611 | 198 of 605 | 1,216 | NCT00561470 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Safety - Number of Patients Experiencing Any Adverse Event | 599 of 600 | 597 of 602 | 1,202 | NCT00154102 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: serious adverse events | 263 of 600 | 204 of 602 | 1,202 | NCT00154102 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Participants With No Residual Tumor After Metastatic Surgery | 29 of 599 | 10 of 599 | 1,198 | NCT00154102 | Trial comparisons |
| Panitumumab Plus FOLFOX vs FOLFOX Alone: serious adverse events | 262 of 585 | 198 of 584 | 1,169 | NCT00364013 | Trial comparisons |
| Arm A: FOLFOX or FOLFIRI + Bevacizumab vs Arm B: FOLFOX or FOLFIRI + Cetuximab: serious adverse events | 98 of 559 | 111 of 578 | 1,137 | NCT00265850 | Trial comparisons |
| FOLFIRI + Ramucirumab vs FOLFIRI + Placebo: serious adverse events | 198 of 529 | 175 of 528 | 1,057 | NCT01183780 | Trial comparisons |
| Panit. Plus Bevacizumab With Chemotherapy vs Bevacizumab With Chemotherapy: serious adverse events | 306 of 518 | 188 of 510 | 1,028 | NCT00115765 | Trial comparisons |
| Cetuximab vs Panitumumab: serious adverse events | 169 of 503 | 151 of 496 | 999 | NCT01001377 | Trial comparisons |
| Cediranib 20 mg vs Placebo: Overall Response Rate | 254 of 502 | 178 of 358 | 860 | NCT00399035 | Trial comparisons |
| Chemotherapy vs Chemotherapy + Bevacizumab: Participants With Progression Free Survival Event | 394 of 410 | 386 of 409 | 819 | NCT00700102 | Trial comparisons |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: Number of Participants With Treatment-emergent Adverse Events (TEAE) | 402 of 404 | 398 of 407 | 811 | NCT02394795 | Trial comparisons |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: deaths from any cause | 14 of 404 | 9 of 407 | 811 | NCT02394795 | Trial comparisons |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: serious adverse events | 115 of 404 | 95 of 407 | 811 | NCT02394795 | Trial comparisons |
| Chemotherapy vs Chemotherapy + Bevacizumab: serious adverse events | 137 of 409 | 130 of 401 | 810 | NCT00700102 | Trial comparisons |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: Number of Participants Treated With Curative Surgical Resection After Chemotherapy | 66 of 400 | 44 of 402 | 802 | NCT02394795 | Trial comparisons |
| TAS-102 vs Placebo: deaths from any cause | 17 of 533 | 30 of 265 | 798 | NCT01607957 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005575/comparisons